| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9416112 | NOVARTIS | 2,4-pyrimidinediamine compounds and their uses |
Jan, 2023
(7 months ago) | |
| US8835430 | NOVARTIS | 2,4-pyrimidinediamine compounds and their uses |
Jan, 2023
(7 months ago) | |
| US9018204 | NOVARTIS | 2,4-pyrimidinediamine compounds and their uses |
Jan, 2023
(7 months ago) | |
| US8188276 | NOVARTIS | 2,4-pyrimidinediamine compounds and their uses |
Jan, 2023
(7 months ago) | |
| US7893074 | NOVARTIS | 2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders |
Apr, 2026
(2 years from now) | |
| US8399450 | NOVARTIS | Compounds and compositions as protein kinase inhibitors |
Nov, 2027
(4 years from now) | |
| US7964592 | NOVARTIS | 2,4-di (phenylamino) pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders |
Apr, 2028
(4 years from now) | |
| US8039479 | NOVARTIS | Compounds and compositions as protein kinase inhibitors |
Jun, 2030
(6 years from now) | |
| US9309229 | NOVARTIS | Crystalline forms of 5-chloro-N2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2, 4-diamine |
Jan, 2032
(8 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8377921 | NOVARTIS | Compounds and compositions as protein kinase inhibitors |
Nov, 2027
(4 years from now) | |
| US8703787 | NOVARTIS | Methods of using ALK inhibitors |
Feb, 2032
(8 years from now) | |
Zykadia is owned by Novartis.
Zykadia contains Ceritinib.
Zykadia has a total of 11 drug patents out of which 4 drug patents have expired.
Expired drug patents of Zykadia are:
- US9416112
- US8835430
- US9018204
- US8188276
Zykadia was authorised for market use on 18 March, 2019.
Zykadia is available in tablet;oral dosage forms.
Zykadia can be used as treatment of a cancer mediated by an anaplastic lymphoma kinase (alk).
The generics of Zykadia are possible to be released after 02 February, 2032.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| ODE* (ODE*) | May 26, 2024 |
Drugs and Companies using CERITINIB ingredient
Market Authorisation Date: 18 March, 2019
Treatment: Treatment of a cancer mediated by an anaplastic lymphoma kinase (alk)
Dosage: TABLET;ORAL
ZYKADIA family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic